TÀI LIỆU THAM KHẢO
Chương 1
1. Vieira NM, Valadares M, Zucconi E, et al. Human adipose-derived
mesenchymal stromal cells injected systemically into GRMD dogs without
immunosuppression are able to reach the host muscle and express human
dystrophin. Cell Transplant. 2012; 21(7): 1407-17. doi: 10.3727/096368911X.
2. Muntoni F, Torelli S, Ferlini A. Dystrophin and mutations: one gene,
several proteins, multiple phenotypes. Lancet Neurol. 2003; 2(12): 731-740.
3. Spuler S, Engel AG. Unexpected sarcolemmal complement membrane
attack complex deposits on nonnecrotic muscle fibers in muscular dystrophies.
Neurology. 1998;50(1):41-46.
4. Skuk D, Vilquin JT, Tremblay JP. Experimental and therapeutic
approaches to muscular dystrophies. Curr Opin Neurol. 2002; 15(5): 563-569.
5. Balaban B, Matthews DJ, Clayton GH, Carry T. Corticosteroid treatment
and functional improvement in Duchenne muscular dystrophy: long-term effect.
Am J Phys Med Rehabil. 2005; 84(11): 843-850.
6 Ricotti V, Ridout DA, Scott E, et al. Long-term benefits and adverse
effects of intermittent versus daily glucocorticoids in boys with Duchenne
muscular dystrophy. J Neurol Neurosurg Physchiatry. 2013; 84(6): 698-705.
7. Ginn SL, Alexander IE, Edelstein ML, Abedi MR, Wixon J. Gene therapy
clinical trials worldwide to 2012 - an update. J Gene. Med. 2013; 15(2): 65-77.
8. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate
allogeneic immune cell responses. Blood. 2005; 105(4): 1815-1822.
9. Caplan AI. Adult mesenchymal stem cells for tissue engineering versus
regenerative medicine. J Cell Physiol. 2007; 213(2): 341-347.
